CROI 2020 Abstract eBook

Abstract eBook

Keyword Index

Outreach 1103 Oxidative phosphorylation 169 Oxidative stress 411 -P- P24 309, 316 Panobinostat 341 Partner notification 42, 938, 944 Partner services 909, 939, 944

Predictive 762 Pre-existing resistance 509 Pregnancy outcomes 790, 793, 794, 1034, 1043 Pregnancy 764, 769, 770, 776, 780, 791, 796, 980, 1034, 1043, 1049, 1057 Pregnant and breastfeeding women 456, 763, 764, 768, 958 Pregnant women 125, 130, 458, 764, 776, 792, 959, 1042 Pre-Exposure Prophylaxis (PrEP) 87, 88, 91, 92, 93, 140, 458, 459, 461, 512, 617, 799, 859, 978, 982, 984, 985, 986, 987, 988, 989, 990, 991, 992, 994, 995, 999, 1002, 1003, 1006, 1007, 1008, 1010, 1011, 1012, 1013, 1014, 1017, 1018, 1019, 1020, 1021, 1022, 1024, 1025, 1026, 1028, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1048, 1053, 1089, 1092, 1098, 1126, 1131 • adherence 878, 977, 980, 987, 991, 993, 1004, 1014, 1027, 1028, 1031 • barriers 987, 995, 1009, 1033 • continuum 995, 1010, 1018, 1019 • discontinuation 978 • eligibility 1019 • implementation 988, 1006, 1007, 1009, 1018 • interest 1033

Randomized trial 417, 771 Rapid

• diagnostic tests 1040 • HIV testing 950, 967 • initiation 498, 1073 • start 1139 Rare pre-existing HIV variants 187 Recency of HIV infection 903, 931, 936, 972, 973 Recent diagnosis 866 Recombinants 933, 936 Record linkage 755 Rectal Recurrence 982 Reengagement in care 46 Refill 1114 Reinfection 595, 596 Remission 77, 79, 319, 325, 348, 387 Renal 822 • biomarker 92 • impairment 1004 • injury 691 • insufficiency 689 • tubular disease 693 • tubular Function 694 Replication 175, 271, 183 Replication-competent reservoir 73, 328 Replicative capacity 186 Reproductive immunology 199 • biopsies 251 • HIV-RNA 257 • infection 997 • microbicides 998 • tissue 213, 464

Partner testing 42, 941 Pathogenesis 188, 614 PBPK 839 PD1 113 PD-1 117, 266, 342, 385 PD-L1 247 Pediatrics 118, 133, 465, 807, 811, 815, 816, 826, 840, 841, 842, 843, 846, 1117 Pelvic inflammatory disease 1056 People living with HIV 33, 469, 740, 1141 People who inject drugs 42, 121, 123, 147, 322, 541, 602, 719, 887, 888, 889, 890, 905, 907, 913, 918, 1023, 1024, 1143 PEPFAR 515, 723, 724, 940, 941, 1037 Periconception 790, 1045 Perinatal HIV infection 134, 136, 394, 444, 766, 778, 809, 814, 823, 831, 832, 837, 1042 Peripheral blood 317 Persistence 37, 190, 308, 314, 316, 327, 335, 352, 363, 365, 377, 383, 811, 878, 982, 1036 PET imaging 29, 72 Pharmacodynamics 461, 468 Pharmacogenetics 456 Pharmacokinetics 88, 129, 144, 452, 455, 456, 458, 461, 464, 465, 466, 468, 470, 471, 473, 508, 775, 839, 842, 843, 846, 847 Pharmacy 957, 1084 Phase I 468, 473, 508 Phenylalanine 703 PHIA 1082 Phylodynamics 364, 915, 916 Phylogenetics 123, 317, 564, 598, 906, 908, 909, 914, 915, 918, Pharmacologic measures 576, 1027 Pharmacovigilance 791, 792, 845

• persistence 978, 991 • readiness 995, 1033 • uptake 978, 988, 995, 1005, 1021, 1023

Prescription 499 Preterm birth 793 Pretomanid 733

Prevalence 752, 857, 879 Prevention impact 865, 901 Prevention 90, 144, 927, 979, 985, 989, 996, 1011, 1016, 1023, 1035, 1038, 1126, 1127 Prevention-of-mother-to child transmission 765, 766, 777, 778 Prevotella 228 Primary cells 358 Primary infection 241 Principal components analysis 243 PRO140 524 Probabilistic sampling 1057

Reservoirs 31, 37, 72, 75, 79, 140, 174, 200, 267, 280, 299, 308, 309, 312, 314, 318, 323, 324, 332, 335, 337, 344, 356, 364, 366, 367, 371, 372, 374, 376, 377, 378, 379, 381, 384, 420, 425, 434, 435, 476, 502, 587, 809, 810, 811, 1055 Reservoir formation 327, 328 Reservoir persistence 340, 368, 406, 431 Resident memoryT cells 318, 332 Residual viremia 257, 310 Resistance 35, 140, 483, 511, 514, 520, 521, 525, 1002, 1052 • mutants 529 • mutation 93, 485, 1052 • resistance-associated mutations (RAMs) 430, 489, 490, 493, 514, 518, 519, 526, 564, 565 Resistin 670 Resource limited settings 93, 1135 Respiratory symptoms 696 Respondent-driven sampling (RDS) 854, 890 Resting memory B cells 298 Resting memory CD4T cells 327 Resting metabolic rate 667 Resting state functional connectivity 32, 387 Restriction factor 19, 21, 176, 326 Retention in care 43, 46, 864, 898, 902, 1010, 1036, 1070, 1086, 1105, 1107, 1113, 1117 Retrovirus 177 Rev 19, 178 Reverse transcription 24 Rhesus macaques 68, 76, 89, 117, 423 Ribosome proteins 300 Rifabutin 735 Rifampicin 450, 846 Rifapentine 144, 726 Rilpivirine 34, 466, 482, 532, 550, 776 Ring 1015 Risk 94, 580, 628, 688, 709, 726, 782, 848, 859, 879, 1024, 1030, 1045, 1095 RNA 180, 326, 439, 464, 885 • packaging 167, 168 • seq 66, 356 Routine testing 1081 Routinely collected clinical markers 972 Rural Uganda 1045 Rural 1141

Probiotic 230 Prodrug 467 Proficiency testing 971 Program evaluation 1058 Progression 294 Proinflammatory cytokines 211 Proliferation 368 Protease inhibitors 430, 676, 793 Protection 114 Proteinuria 690 Proteomics 80, 304, 408 Proviral • decay 308 • DNA 328, 375, 485 • landscape 365, 366, 811 • structure 360 • total DNA 311 Provirus 75, 173, 363, 373, 395 PSGL-1 19 Psoriasis 713 Psychiatric disorders 600, 670, 897 Psychosocial tests 401 PTSD 702 Public Health 123, 908, 920, 1008 Pulmonary 236

919, 920, 927, 930, 933, 934, 935 Phylogeography 364, 906, 921, 924 Physical activity 392, 675 Physical function 238, 683, 706, 707 PI3K inhibitors 354 PI-containing ARV regimens 474

PK-PD 999 Plaque 638 Plasma • ARV detection 1084

• biomarkers 300 • membrane 21 • viremia 120, 315 Plasmacytoid dendritic cell 203, 301 Platelets 190, 434, 445 Pluripotency 789 PLWH 596 PLX3397 420 PMTCT 776, 779 Point-of-care 91, 132, 133, 446, 783, 785, 951, 952, 954, 1050, 1087, 1090 Policy 513 Poly/auto-reactivity 263 Polycomb repressor complex 2 331 PolyfunctionalT cell 295 Pomalidomide 70 Pooled HCV RNA 591

Keyword Index

• disease 196, 699 • function 699, 742

• hypertension 654, 700 • tuberculosis 265, 740 -Q- QPCR 812 Qualitative research 960 Quality 656 Quality of care 1080 Quality of life 698 Quantification 970 Quasispecies 179 Questionnaire 947 QVOA 313, 385 -R- Race 678 Race/Racial differences 146

PopART 850, 976, 1076 Population 148, 848, 1049 • attributable fraction 675 • effectiveness 1037 • level impact 134, 150 • pharmacokinetics 458, 729, 733

• size estimation 905 • viral load 150, 865 Positivity 948 Postexposure prophylaxis (PEP) 87, 88, 89, 140, 617, 996

Ruxolitinib 452 RV144 287, 289 Rwanda 1071 RyanWhite HIV/AIDS program 1141 -S- Safer conception 1058 Safety 144, 504, 844, 847 Same-day therapy 974, 1071, 1072, 1074 Sarcopenia 542

Post-migration HIV-1 acquisition 921 Postpartum 131, 771, 772, 780, 980 Posttraumatic stress disorder 702 Post-treatment control 319, 321, 325 PPARγ antagonist 351

Rakai, Uganda 950 Raltegravir 494, 846 Randomized controlled trial 132, 497, 514, 732, 901, 1063, 1070 Randomized open-label trial 136

Pre diabetes 682 Preclinical 87, 504 Predictive model 902, 1007

CROI 2020 466